Close

Latest Zandelisib TIDAL Data "Impressive, Supports Outlook" - Brookline Capital Markets Reiterates MEI Pharma (MEIP) at Buy with $15 Price Target Jun 6, 2022 06:35AM
Brookline Capital Markets Reiterates Buy Rating, $15 Price Target on MEI Pharma (MEIP), Sees "Upside to Longer-Term Outlook" from ME-344 Contributions Apr 12, 2022 09:09AM
"Near-Term Zandelisib Launch off the Table" After "Bewildering" FDA Feedback - MEI Pharma (MEIP) Stock Crashes as Analysts Downgrades Roll In Mar 25, 2022 10:04AM
MEI Pharma (MEIP) PT Lowered to $3 at Truist Securities on zandelisib Delay, but Maintains Conviction in Drug, Sees Peak Sales of $94M Mar 25, 2022 06:15AM
MEI Pharma’s (MEIP) zandelisib Has Best-in-Class Potential, Poised to Dominate the Space - Analyst Nov 30, 2021 07:44AM